Here are three things to know.
- Mydayis is intended to treat ADHD symptoms in patients thirteen years or older.
- The once-daily drug features the same active ingredients as Shire’s popular ADHD drug Adderall, but is formulated to last up to 16 hours, according to Reuters.
- Shire plans to launch Mydayis in the third quarter of this year.
More articles on supply chain:
Global drug sales forecast falls for 1st time in decade
Stryker to acquire imaging technology company for $701M
SCOTUS decision reduces drugmakers’ product liability
Register to Attend Webinar
Presenters:
Joel Ray, COL, USAF, NC, MSN, RN, NEA-BC, Laudio and StaffGarden by Ascend Learning|Larissa Africa, MBA, RN, CENP, FAONL, FAAN, StaffGarden by Ascend Learning|Alicia Potolsky, DNP, RN, NE-BC, DipACLM, El Camino Health|Julie Balluck, DNP, RN, NEA-BC, Texas Health Resources
Next Up in Supply Chain
-
Ville Platte, La.-based Mercy Regional Medical Center has signed a prime vendor agreement with Medline for medical-surgical products and distribution…
-
Three group purchasing organizations served as the primary GPOs for more than 80% of U.S. hospitals in 2024, according to…
-
The federal government has invested $15.97 million in a project designed to establish a fully domestic pharmaceutical supply chain in…
Join the 500,000+ healthcare executives who start their day with Becker's
Becker's Hospital Review Newsletter is sent Monday–Sunday.
